Skip to content

Relacorilant

DRUG15 trials

Sponsors

Corcept Therapeutics Inc., Corcept Therapeutics, University of Chicago, ARCAGY/ GINECO GROUP

Conditions

AdenocarcinomaAdrenocortical CarcinomaAdvancedCarcinoma, Pancreatic DuctalCushing SyndromeGynecological CancersHealthyHepatic Impairment

Phase 1

Phase 2

Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome
Active, not recruitingNCT03604198
Corcept TherapeuticsCushing Syndrome
Start: 2018-05-07End: 2026-12-01Updated: 2026-08-25
Study of Relacorilant in Combination With Nab-Paclitaxel for Patients With Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
CompletedNCT03776812
Corcept TherapeuticsRecurrent Fallopian Tube Carcinoma, Recurrent Ovarian Cancer, Recurrent Primary Peritoneal Carcinoma
Start: 2019-04-05End: 2023-07-12Updated: 2025-10-07
A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer
RecruitingNCT05726292
University of ChicagoProstate Adenocarcinoma, Prostate Cancer
Start: 2025-01-06End: 2028-04-01Target: 90Updated: 2026-08-31
An Open-label, Global, Multi-Arm Study to Evaluate the Efficacy and Safety of Relacorilant in Combination with Different Treatment Regimens in Patients with Gynecological Cancers (BELLA)
RecruitingCTIS2024-517432-21-00
Corcept Therapeutics Inc.Gynecological Cancers
Start: 2025-05-30Target: 177Updated: 2026-01-27
Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma
RecruitingNCT07259317
Corcept TherapeuticsAdenocarcinoma, Carcinoma, Pancreatic Ductal
Start: 2026-01-27End: 2027-09-01Target: 80Updated: 2026-08-18
Relacorilant and Nab-Paclitaxel in Recurrent or Metastatic Cervical Cancer
Not yet recruitingNCT07763496
ARCAGY/ GINECO GROUPRecurrent or Metastatic Cervical Cancer
Start: 2026-10-01End: 2030-12-01Target: 63Updated: 2026-08-13

Phase 3

Related Papers

2 more papers not shown